SCHEDULE: RTW Investments Cuts Acadia Pharma Stake to 4.2%

RTW Investments and Roderick Wong reported a reduced beneficial ownership of 4.2% in Acadia Pharmaceuticals Inc. common stock.

Summary

• RTW Investments, LP and Roderick Wong reported beneficial ownership of 7,144,524 shares of Acadia Pharmaceuticals Inc. common stock.
• This represents 4.2% of the class of securities, based on 168,712,220 shares outstanding as of July 30, 2025.
• The filing is an Amendment No. 3 to a Schedule 13G, indicating a change from a previous beneficial ownership position.
• RTW Investments, LP is a Delaware limited partnership and an investment adviser to certain funds (RTW Funds).
• Roderick Wong, M.D., is the Managing Partner and Chief Investment Officer of RTW Investments, LP and a U.S. citizen.
• Both RTW Investments and Dr. Wong share voting and dispositive power over the 7,144,524 shares.

Sentiment

Score: 4

Explanation: The sentiment is slightly negative due to the reduction in beneficial ownership by a significant institutional investor, which can be interpreted as a lack of continued conviction in the company's near-term prospects.

Positives

• NA

Negatives

• RTW Investments, LP and Roderick Wong reduced their beneficial ownership in Acadia Pharmaceuticals Inc. to 4.2% of the common stock. This indicates a reduction from a previous stake that was likely above 5%, given this is an amendment and they now report below the 5% threshold.
• This reduction in stake by a significant institutional investor could be perceived negatively by the market, potentially signaling a decrease in conviction or a strategic divestment.

Risks

• NA

Future Outlook

NA

Industry Context

Acadia Pharmaceuticals Inc. operates in the biotechnology and pharmaceutical sector, focusing on the development and commercialization of therapies for central nervous system disorders. The filing reflects an institutional investor's position within this specialized industry.

Stakeholder Impact

• Shareholders may interpret the reduction in institutional ownership as a negative signal, potentially impacting investor confidence and stock valuation.
• The market may react to the news of a significant investor reducing their stake, leading to potential downward pressure on the share price.

Key Dates

Recommendation

The filing indicates a reduction in beneficial ownership by a significant institutional investor, RTW Investments, to below 5%. While this is a notable event, a Schedule 13G amendment alone does not provide sufficient comprehensive financial or operational data to warrant a strong buy or sell recommendation. Investors should monitor future filings and company performance for a more complete picture. A 'hold' recommendation reflects a cautious stance, acknowledging the negative signal of reduced institutional interest while awaiting further information.

Keywords

Acadia Pharmaceuticals, RTW Investments, Roderick Wong, Beneficial Ownership, Schedule 13G, Common Stock, Investment Adviser, Biotechnology, Pharmaceuticals